Valerius T - Search Results

1

Bispecific antibodies targeting cancer cells.

Peipp M, Valerius T. Peipp M, et al. Among authors: valerius t. Biochem Soc Trans. 2002 Aug;30(4):507-11. doi: 10.1042/bst0300507. Biochem Soc Trans. 2002. PMID: 12196124 Review.

2

Neutrophils express the high affinity receptor for IgG (Fc gamma RI, CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor.

Repp R, Valerius T, Sendler A, Gramatzki M, Iro H, Kalden JR, Platzer E. Repp R, et al. Among authors: valerius t. Blood. 1991 Aug 15;78(4):885-9. Blood. 1991. PMID: 1714327 Free article.

3

G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210).

Repp R, Valerius T, Wieland G, Becker W, Steininger H, Deo Y, Helm G, Gramatzki M, Van de Winkel JG, Lang N, et al. Repp R, et al. Among authors: valerius t. J Hematother. 1995 Oct;4(5):415-21. doi: 10.1089/scd.1.1995.4.415. J Hematother. 1995. PMID: 8581378 Review.

4

HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor.

Elsässer D, Valerius T, Repp R, Weiner GJ, Deo Y, Kalden JR, van de Winkel JG, Stevenson GT, Glennie MJ, Gramatzki M. Elsässer D, et al. Among authors: valerius t. Blood. 1996 May 1;87(9):3803-12. Blood. 1996. PMID: 8611706 Free article.

5

Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer.

Stockmeyer B, Valerius T, Repp R, Heijnen IA, Bühring HJ, Deo YM, Kalden JR, Gramatzki M, van de Winkel JG. Stockmeyer B, et al. Among authors: valerius t. Cancer Res. 1997 Feb 15;57(4):696-701. Cancer Res. 1997. PMID: 9044847

6

HLA class II antibodies recruit G-CSF activated neutrophils for treatment of B cell malignancies.

Valerius T, Elsässer D, Repp R, Van de Winkel JG, Gramatzki M, Glennie M. Valerius T, et al. Leuk Lymphoma. 1997 Jul;26(3-4):261-9. doi: 10.3109/10428199709051775. Leuk Lymphoma. 1997. PMID: 9322888 Review.

7

FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy.

Valerius T, Stockmeyer B, van Spriel AB, Graziano RF, van den Herik-Oudijk IE, Repp R, Deo YM, Lund J, Kalden JR, Gramatzki M, van de Winkel JG. Valerius T, et al. Blood. 1997 Dec 1;90(11):4485-92. Blood. 1997. PMID: 9373259 Free article.

8

Activated neutrophils as effector cells for bispecific antibodies.

Valerius T, Würflein D, Stockmeyer B, Repp R, Kalden JR, Gramatzki M. Valerius T, et al. Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):142-5. doi: 10.1007/s002620050417. Cancer Immunol Immunother. 1997. PMID: 9435858 Free PMC article. No abstract available.

9

Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells.

Würflein D, Dechant M, Stockmeyer B, Tutt AL, Hu P, Repp R, Kalden JR, van de Winkel JG, Epstein AL, Valerius T, Glennie M, Gramatzki M. Würflein D, et al. Among authors: valerius t. Cancer Res. 1998 Jul 15;58(14):3051-8. Cancer Res. 1998. PMID: 9679970

10

Preclinical studies combining bispecific antibodies with cytokine-stimulated effector cells for immunotherapy of renal cell carcinoma.

Elsässer D, Stadick H, Stark S, Van de Winkel JG, Gramatzki M, Schrott KM, Valerius T, Schafhauser W. Elsässer D, et al. Among authors: valerius t. Anticancer Res. 1999 Mar-Apr;19(2C):1525-8. Anticancer Res. 1999. PMID: 10365137

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

180 results

Search Page

Filters